GSK’s bepirovirsen represents a significant advancement in hepatitis B treatment, with three critical takeaways for clinicians and patients. First, the functional cure rate of 18% substantially exceeds the 1% achievement rate of current therapies, offering hope for better long-term outcomes. Second, the drug employs antisense RNA technology—a novel mechanism that directly targets viral RNA and prevents replication, contrasting sharply with conventional nucleoside analogues that suppress without eliminating the virus. Third, phase 3 trials are anticipated to launch within 12 months, potentially accelerating regulatory review and clinical availability. These findings carry particular weight given chronic hepatitis B’s status as a leading cause of liver cancer and cirrhosis globally. Healthcare providers should remain informed about this emerging therapy’s progress, while patients may benefit from discussing potential participation in upcoming trials with their physicians. Read the full article on GMJ Newsroom.
Was this article helpful?
